RPG Life Sciences Ltd

RPG Life Sciences Ltd (formerly Searle India Ltd) began operations in 1968 as a joint venture with GD Searle USA. After 1993 GD Searle withdrew and sold its holdings to the RPG Group. The company is involved in the manufacturing and marketing of Formulations Finished Dosage Forms and Active Pharmaceutical Ingredients APIs. It has research and development facilities which are internationally compliant, such as Biotech RD API RD and Formulations RD, as well as TGA Aus and MHRA UK approved facilities in Thane in Maharashtra and Ankleshwar in Gujarat. In 2008 the equity shares of the company were listed on BSE and NSE, and in 2009-2010 the company increased the production capacity of Bulk Drugs and Chemicals from 62 to 71 tonnes. They launched an oncology drug, Exemestane, as well as Nufex Beta QugylO Immunotec. Adding to it, during the year 2009-2010, 11 new products across a range of therapeutic segments were launched, such as Demator Sizomax Mela Exinia and Mofetyl S, and they also launched a new immunosuppressant product Sirolimus during the same year. New divisions in the highly growing chronic segments Cardiology, Diabetic, Neurology-Psychiatry, Oncology were also launched. The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 2016-2017 and acquired 7 brands from Sun Pharmaceuticals Limited the same year. In 2017-2018, the Company launched two new brands Darbepoetin and RituximabXMAB in the post-transplant care space. It also launched a new product TJAKi JAK Inhibitor in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21, and Azoran 75 mg new line extension was also launched in 2021. Naprosyn and AldactoneF were launched in FY22.

Revenue: ₹176.89Cr as on March 2026 (Q4 FY26)
Net Profit: ₹29.90Cr as on March 2026 (Q4 FY26)
Listing date: 10 Jun, 2008
Chairperson Name: H V Goenka